Holen Sie sich die Stockscreener-App
8.32
5.78%
-0.51
Handel nachbörslich:
8.20
-0.12
-1.44%
Schlusskurs vom Vortag:
$8.83
Offen:
$8.83
24-Stunden-Volumen:
1.91M
Relative Volume:
2.47
Marktkapitalisierung:
$447.98M
Einnahmen:
$20.72M
Nettoeinkommen (Verlust:
$-100.84M
KGV:
-2.5366
EPS:
-3.28
Netto-Cashflow:
$-78.56M
1W Leistung:
+3.10%
1M Leistung:
-2.46%
6M Leistung:
-67.17%
1J Leistung:
-31.75%
1-Tages-Spanne:
$8.185
$9.1799
1-Wochen-Bereich:
$7.32
$9.1799
52-Wochen-Spanne:
$7.32
$36.25
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Firmenname
4 D Molecular Therapeutics Inc
Sektor
Branche
Telefon
(510) 505-2680
Adresse
5858 HORTON STREET #455, EMERYVILLE
Vergleichen Sie FDMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| FDMT | 8.32 | 447.98M | 20.72M | -100.84M | -78.56M | -3.28 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-07 | Fortgesetzt | Goldman | Buy |
| 2023-10-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-12 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Eingeleitet | Jefferies | Buy |
| 2022-01-04 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-05 | Eingeleitet | Goldman | Neutral |
Alle ansehen
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
FY2024 Earnings Forecast for FDMT Issued By Leerink Partnrs - MarketBeat
HC Wainwright Has Negative Outlook for FDMT FY2024 Earnings - MarketBeat
4D Molecular Therapeutics’ Positive Q3 and Strategic Advances - TipRanks
RA Capital Management, L.P. Increases Stake in 4D Molecular Ther - GuruFocus.com
Janus Henderson Group PLC's Strategic Adjustment in 4D Molecular Therapeutics Inc Holdings - GuruFocus.com
Analyst Expectations For 4D Molecular Therapeutics's Future - Benzinga
Deep Track Capital, LP Increases Stake in 4D Molecular Therapeutics Inc - GuruFocus.com
4D Molecular Sets Major Conference Schedule: Jefferies, Evercore & OIS XIV Appearances | FDMT Stock News - StockTitan
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates - MSN
4D Molecular Therapeutics Inc Reports Q3 2024 EPS of $(0.79) and Revenue of $3,000 - GuruFocus.com
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Reports Positive AMD Trial Data, $551M Cash Position Funds Operations to 2027 | FDMT Stock News - StockTitan
4D Molecular Therapeutics stock hits 52-week low at $7.9 By Investing.com - Investing.com Australia
4D Molecular Therapeutics stock hits 52-week low at $7.9 - Investing.com India
4D Molecular Therapeutics Inc. (FDMT) Quarterly 10-Q Report - Quartz
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $47.14 Consensus PT from Analysts - MarketBeat
BioSpace Announces 2025 Best Places to Work in Biopharma - BioSpace
X-Linked Retinitis Pigmentosa Clinical Trials 2024: FDA - openPR
Goldman Sachs Group Inc's Strategic Reduction in 4D Molecular Th - GuruFocus.com
Vanguard Group Inc's Strategic Acquisition of Shares in 4D Molec - GuruFocus.com
We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely - Yahoo Finance
Fabry Disease Market to grow at a CAGR of ~6% by 2032, analyzes - openPR
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 13.2% in October - MarketBeat
Assenagon Asset Management S.A. Has $16.68 Million Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations - StockTitan
nVerses Capital LLC Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts
4D Molecular Therapeutics stock hits 52-week low at $8.52 By Investing.com - Investing.com Australia
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
4D Molecular Therapeutics stock hits 52-week low at $8.52 - Investing.com India
Gene therapy for managing neovascular macular degeneration - Ophthalmology Times Europe
Recent Insider Activity Suggests Potential Gains for 4D Molecular Therapeutics Inc (FDMT) - Knox Daily
4D Molecular Therapeutics Inc (FDMT)’s Day in Review: Closing at 9.17, Up by 5.04 - The Dwinnex
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? - Yahoo Finance
Prospect Capital Corp [PSEC] Investment Guide: What You Need to Know - Knox Daily
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Stock Is A Good Option To Consider - Stocks Register
Looking For A Top Momentum Stock? Check Out Service Properties Trust (NASDAQ: SVC) - Stocks Register
Metrics That Matter About Roper Technologies Inc (NASDAQ: ROP) - Stocks Register
FTAI Infrastructure Inc (NASDAQ: FIP) Is A Blank Check For Growth - Stocks Register
This trade activity should not be overlooked: 4D Molecular Therapeutics Inc (FDMT) - SETE News
4D Molecular Therapeutics Inc (FDMT)’s stock decline to 9.26 per share - US Post News
4D Molecular Therapeutics Inc (FDMT) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
4D Molecular Therapeutics stock hits 52-week low at $9.41 By Investing.com - Investing.com UK
Market Insights: 4D Molecular Therapeutics Inc (FDMT)’s Notable Drop of -3.58, Closing at 9.97 - The Dwinnex
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics Inc (FDMT) to a Neutral from an Overweight - Knox Daily
Dimensional Fund Advisors LP Sells 216,250 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 3.8%What's Next? - MarketBeat
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy FailureI'm Not So Sure - Seeking Alpha
4D Molecular Therapeutics, Inc. Is Being Investigated For Possib - WICZ
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by Squarepoint Ops LLC - MarketBeat
Marshall Wace LLP Trims Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
Finanzdaten der 4 D Molecular Therapeutics Inc-Aktie (FDMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):